Skip to content
    Clinical Trials

    PREMIUM Trial: Abbreviated MRI vs Ultrasound for HCC Screening in Cirrhosis

    Dunn et alAbdominal Radiology

    PREMIUM Trial: Abbreviated MRI vs Ultrasound for HCC Screening in Cirrhosis
    The Preventing Liver Cancer Mortality through Imaging with Ultrasound versus MRI (PREMIUM) study is a Department of Veterans Affairs–sponsored, multicenter randomized controlled trial designed to evaluate whether hepatocellular carcinoma (HCC) screening with dynamic contrast-enhanced abbreviated MRI (DCE-aMRI) plus serum alpha-fetoprotein (AFP) reduces HCC-related mortality compared to standard ultrasound (US) plus serum AFP in patients with cirrhosis. The trial aims to enroll 4,700 participants across more than 47 VA Medical Centers, randomizing them to semiannual surveillance for up to eight years with HCC-related mortality as the primary endpoint. Currently, 35 sites are active, and 1,085 patients have been randomized.
    To maintain consistency in trial execution and per-protocol screening across centers, the PREMIUM Radiology Workgroup established standardized imaging protocols, structured LI-RADS–based reporting templates, and centralized training for radiologists and technologists, backed by continuous quality control of imaging acquisition and interpretation. The DCE-aMRI protocol employs multiphasic post-contrast imaging to enable LI-RADS scoring; a non-contrast-enhanced aMRI option is provided for patients who encounter contrast allergies or renal function decline. Ultrasound protocols adhere strictly to US LI-RADS specifications. Structured reporting standardizes documentation of observations, visualization scores, and clinical follow-up recommendations. Additionally, a centralized Image Repository utilizing advanced de-identification algorithms to erase metadata and pixel-embedded protected health information is anticipated to archive over 20,000 liver MRI and US scans, providing a research platform for secondary trial outcomes, radiomics, and artificial intelligence development.

    Key Takeaways

    • To date, the Department of Veterans Affairs PREMIUM trial has activated 35 sites and randomized 1,085 patients toward a planned enrollment of 4,700 participants receiving semiannual screening over up to eight years.
    • Standardized abbreviated MRI protocols incorporate multiphasic post-contrast imaging for LI-RADS scoring, with a non-contrast option designated for participants who develop renal impairment or contrast allergies during the study.
    • A centralized, de-identified imaging repository is set to collect over 20,000 curated liver MRI and ultrasound examinations to assess primary outcomes and enable downstream radiomics and artificial intelligence research.
    Read the original sourceAbdominal Radiology